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a  b  s  t  r  a  c  t
Various studies have demonstrated the impact of omega-3 fatty acids on the concentration
of  C reactive protein (CRP), pro-inﬂammatory eicosanoids, cytokines, chemokines and other
inﬂammatory mediators. Therefore, the supplementation of these types of lipids may rep-
resent additional option treatment for chronic systemic diseases, such as Systemic Lupus
Erythematous and other rheumatic diseases. The role of these lipids has not been well
established, yet. However, it seems there is a direct relationship between its intake and
the  decrease of the disease clinical manifestations as well as of the inﬂammatory status
of  the patients. Thus, the aim of this manuscript is to present a thorough review on the
effects of omega-3 fatty acids in patients with SLE. Bibliographic data set as the Medical Lit-
erature Analysis and Retrieval System Online (MEDLINE) and Literatura Latino-Americana
e  do Caribe em Ciências da Saúde (LILACS) were searched using as key words: systemic
lupus erythematous (SLE), polyunsaturated fatty acids omega-3, eicosapentanoic acid (EPA),
docosahexanoic acid (DHA), antioxidants and diet. Manuscripts published up to September
2013 were included. There were 43 articles related to the topic, however only 15 pertainedhuman studies, with three review articles and 12 clinical studies.
© 2014 Elsevier Editora Ltda. All rights reserved.DOI of original article: http://dx.doi.org/10.1016/j.rbr.2013.12.002.
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Ácidos  graxos  poli-insaturados  ômega-3  e  lúpus  eritematoso  sistêmico:  o
que  sabemos?
Palavras-chave:
Lúpus eritematoso sistêmico
(LES)
Ácidos graxos poli-insaturados
ômega-3
Ácido eicosapentaenoico (EPA)
Ácido docosahexaenoico (DHA)
Antioxidantes
r  e  s  u  m  o
Diversos estudos têm demonstrado a habilidade dos ácidos graxos ômega-3 em reduzir
as  concentrac¸ões de proteína C-reativa (PCR), eicosanoides pró-inﬂamatórios, citoci-
nas,  quimiocinas e de outros biomarcadores da inﬂamac¸ão. Por essas propriedades, a
suplementac¸ão  com essa classe de lipídeos pode representar terapia adicional ao trata-
mento de doenc¸as inﬂamatórias crônicas sistêmicas, como o lúpus eritematoso sistêmico
(LES) e outras doenc¸as reumáticas. O papel dessa classe de lipídeos no LES ainda não está
bem estabelecido. No entanto, parece haver relac¸ão entre o consumo deste tipo de gordura
e  a diminuic¸ão das manifestac¸ões e da atividade inﬂamatória da doenc¸a. Sendo assim, este
artigo apresenta revisão da literatura cientíﬁca sobre os efeitos dos ácidos graxos ômega-3
em  pacientes com LES. Realizou-se levantamento bibliográﬁco junto aos bancos de dados
Medical Literature Analysis and Retrieval System Online (MEDLINE) e Literatura Latino-
Americana e do Caribe em Ciências da Saúde (LILACS), utizando-se como palavras-chave:
lúpus eritematoso sistêmico (LES), ácidos graxos poli-insaturados ômega-3, ácido eicos-
apentaenoico (EPA), ácido docosahexaenoico (DHA), antioxidantes e dieta. Foram incluídos
artigos publicados até setembro de 2013. Quarenta e três artigos relacionados ao tema foram
encontrados. Após limitar a busca apenas para estudos realizados em seres humanos foram
encontrados 15 artigos, sendo três de revisão e 12 ensaios clínicos.
©  2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Beneﬁcial effects of omega-3 polyunsaturated fatty acids have
been extensively studied, mostly those acting on the cardio-
vascular system.1–4 Over the last few years, the interest in the
role of this nutrient in reducing inﬂammation has grown.5
These fatty acids are considered essential and should be
provided by the diet or from supplements. They compete with
the arachidonic acid (AA), a member of the omega-6 family
through the same enzymatic pathway and stimulate series 3
prostaglandins and series 5 leukotrienes, which have a lower
inﬂammatory action than those AA-derived eicosanoids.6
Several studies have demonstrated that omega-3 fatty
acids can reduce the concentrations of C reactive protein
(CRP), proinﬂammatory eicosanoids, cytokines, chemokines,
and other inﬂammatory biomarkers.7–10 In addition, eicosa-
pentaenoic acid (EPA) and docosahexaenoic acid (DHA), both
members of omega-3 family, are precursors of the lipid medi-
ators resolvins and protectins, which have anti-inﬂammatory
and immunomodulatory characteristics.11–13
In view of these properties, supplements with this class
of lipids might represent an additional therapy of systemic
chronic inﬂammatory diseases, such as systemic lupus ery-
thematosus (SLE) and other rheumatic conditions. Studies
conducted in subjects with rheumatoid arthritis report an
improvement in general physical evaluation, pain, morning
stiffness and reduced anti-inﬂammatory agent use following
supplementation with omega-3.14–16The role of these fatty acids in SLE is not fully established
yet. However, the intake of this kind of fat seems to be related
to the reduction in disease manifestations and inﬂammatory
activity.17–25The authors present a literature review on the effects of
omega-3 fatty acids on patients with SLE.
Method
A literature search on MEDLINE and LILACS databases was
performed with the following keywords: systemic lupus
erythematosus (SLE), omega-3 polyunsaturated fatty acids,
eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA),
antioxidants, and diet. Articles published up to September
2013 were included. Forty-three articles related to the topic
have been identiﬁed. After the search was limited to studies
conducted in humans, 15 articles were found, with three of
them being review articles and 12 clinical trials.
Systemic  Lupus  Erythematosus
Systemic lupus erythematosus (SLE) is a multisystemic
autoimmune inﬂammatory disease with a large spectrum of
manifestations that is clinically characterized by relapses and
remission periods with a varying course and outcome. The dis-
ease severity ranges from mild to severe. However, complete
and prolonged remission is rare.26
Although SLE etiology is not known, an interaction of
genetic, hormonal and environmental factors are probably
involved in the disease development, thus leading to a loss of
cell immunoregulation balance.27 This immune disturbance
occurs through loss of tolerance to nuclear antigens, poorly
regulated activation of B- and T lymphocytes and subsequent
B-lymphocyte polyclonal activation, with large numbers of
reactive self-antibodies being produced and immune com-
plex being formed. The immune complexes, along with
 . 2 0 1 4;5 4(6):459–466 461
s
o
c
r
l
a
h
s
i
p
r
a
I
e
c
a
m
g
m
a
a
O
F
b
p
b
a
a
a
f
a
(
[
f
O
t
(
f
v
i
o
o
w
h
a
c
M
T
f
i
a
l
a
Family w-3
Delta 6 desaturase
Delta 5 desaturase
Delta 6 desaturase
Family w-6
18:3 (α-linolenic acid) 18:2 (linoleic acid)
20:4 (arachidonic acid–AA) 20:5 (eicosapentaenoic acid–EPA)
22:6 (docosahexaenoic acid–DHA)
18:4
Elongase
Elongase
Elongase
Beta-oxidation 
20:4
22:5
18:3
20:3
22:4
24:4
24:5
22:5
24:5
24:6
Figure 1 – Omega-3 and omega-6 fatty-acid metabolismr e v b r a s r e u m a t o l
elf-antibodies, are primarily responsible for tissue lesion and
rgan damage.28
This complex process involves interaction of various
ytokines, chemokines, adhesion molecules, and pattern-
ecognition receptors (PRRs) triggering cell activation.29
T lymphocytes with a TH1 functional response are stimu-
ated by interleukin (IL)-12 to produce tumor necrosis factor
lpha (TNF-), interferon gamma (IFN-), and IL-2. On the other
and, TH2 lymphocytes produce IL-4, IL-5, and IL-13 when
timulated by IL-4. A signiﬁcant cytokine elevation result-
ng from the TH1 response is observed in the serum of
atients with SLE, thus indicating a disturbance in TH1/TH2
esponse pattern is likely.28 The TH17 functional response
nd serum levels of other cytokines, such as IL-23, IL-18,
L-21, and IL-23 are also elevated, but their role in the dis-
ase pathogenesis is still under investigation.28 Many  of these
ytokines are elevated in the serum of patients with SLE and
re associated with a higher disease activity or certain clinical
anifestations.29–32
Few studies analyzed the role of nutrition in SLE patho-
enesis to this moment. Omega-3 polyunsaturated fatty acids
ight have beneﬁcial clinical effects on SLE because of their
nti-inﬂammatory actions, which would warrant their use as
nother treatment option for the disease.13
mega-3  polyunsaturated  fatty  acids
atty acids may be classiﬁed as saturated (no double bonds
etween individual carbon atoms) fatty acids and mono- or
olyunsaturated fatty acids according to the number of dou-
le bonds in the chain. The most common saturated fatty
cids in human food are: lauric, myristic, palmitic, and stearic
cids (ranging from 12 to 18 carbon atoms). Unsaturated fatty
cids are classiﬁed into two main categories: polyunsaturated
atty acids, represented by omega-6 fats (with main represent-
tives being linoleic and arachidonic acids) and omega-3 fats
with main representatives being -linolenic, eicosapentaenoic
EPA], and docosahexaenoic [DHA] acids) or monounsaturated
atty acids, represented by the omega-9 (omega-9 – oleic) fats.
mega-3 and omega-6 fatty acids are considered essential, as
hey are not synthesized by the human body. The linoleic acid
18:2 omega-3) is the precursor of the other polyunsaturated
atty acids in omega-6 fats, which has soy, corn, and sunﬂower
egetable oils as their main food sources. In the omega-3 fam-
ly, the -linolenic acid (18:3 omega-3) is found in a number
f vegetables, such as canola and linseed, whereas EPA (20:5
mega-3) and DHA (22:6 omega-3) are found in deep sea cold
ater ﬁsh (mackerel, sardines, salmon, herring). On the other
and, oleic acid (18:1 omega-9) can be synthesized by the body
nd its main diet sources are olive oil, canola oil, olives, avo-
ado and nuts (peanuts, chestnuts, walnuts, almonds).33
echanisms  of  action  of  omega-3  fatty  acids
he ﬁrst data suggesting a possible anti-inﬂammatory role
or omega-3 fatty acids are derived from an epidemiolog-
cal study in Greenland Eskimos conducted by Kronmann
nd Green in 1980. The authors found that the preva-
ence of diseases with an inﬂammatory component, such as
cute myocardium infarction, diabetes mellitus (DM), multipleAdapted from Leonard et al., 2004.37.
sclerosis, bronchial asthma, and thyrotoxicosis, was lower in
the study population than in Western country populations.
Eskimos diet have a large amount of seafood, which is a source
of polyunsaturated fatty acids.34 Thereafter, several studies
were conducted to ﬁnd the role of these lipids in many  chronic
diseases in which inﬂammation plays a major pathogenetic
role.
The omega-3 and omega-6 families, through their mem-
bers EPA, DHA, and arachidonic acid (AA), are the essential
lipid classes for eicosanoid synthesis. Eicosanoids are among
the major inﬂammation mediators and regulators. They
include prostaglandins (PG), leukotrienes (LT), thromboxanes,
and other oxidized derivatives. They are produced by oxidative
pathways of the enzymes cyclooxygenase (COX) and lipoxyge-
nase (LOX).35
Due to their molecular similarity, linoleic acid and -
linolenic acid compete for the same enzymes to synthesize
derivatives with 20 carbon atoms: AA (20:4 omega-6), eico-
sapentaenoic acid (EPA) (20:5 omega-3) e eicosatrienoic acid
(ETA) (20:3 omega-9). The -linolenic acid has a 22-carbon
atom derivative, the docosahexaenoic acid (DHA) (22:6 omega-
3)33,36,37 (Fig. 1).
A high intake of linoleic acid favors an increased AA
content in membrane phospholipids, thus increasing the
production of series 2 and 4 eicosanoids (prostaglandin E2
and leukotriene B4) through cyclooxygenase and lipoxyge-
nase enzymatic pathways, respectively. A high production
of eicosanoids is related to the occurrence of immune dis-
orders, cardiovascular and inﬂammatory diseases. On the
other hand, the intake of omega-3 family fatty acids, such
as -linolenic acid, EPA or DHA, which compete with AA
for the same enzymatic pathways, competitively inhibits
the arachidonic acid oxidation by cyclooxygenase (COX) into
prostaglandins and their conversion into leukotrienes (LTs)
via 5-lipoxygenase (LOX) pathway.6,33 The omega-6 fatty acid
leads to proinﬂammatory series 2 and 4 eicosanoid pro-
duction [PGE2, thromboxane A2 (TXA2) and leukotriene B4
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Arachidonic Acid      EPA DH A
Series-2 PGs Series-4 LTs Series-3 PGs Series-5 LTs Series-E resolvins Series-D resolvins 
and protectins
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Figure 2 – Syntheses and actions of lipid mediators produced by AA, EPA, and DHA
AA, arachidonic acid; EPA, eicosapentaenoic acid; DHA, docoxahexaenoic acid; COX, cyclooxygenase; LOX, lipoxygenase;
PG, prostaglandins; LT, leukotrienes
13Adapted from Calder et al., 2010. .
(LTB4)]. PGE2 induces a number of proinﬂammatory effects,
such as increased vascular permeability, vasodilation, hyper-
emia, and hiperalgesia.38–40 TXA2 promotes the synthesis of
inﬂammatory cytokines, IL-1 and TNF- by mononuclear
phagocytes.39,41 On the other hand, LTB4, in addition to
causing increased vascular permeability and hyperemia, is a
powerful leukocyte chemotactic agent inducing the produc-
tion of lysosomal enzymes and increasing the production of
reactive oxygen species and cytokines, such as TNF-, IL-1, and
IL-6 (Fig. 2).39,40
Thus, the omega-3 fatty acid acts by reducing the forma-
tion of eicosanoids with inﬂammatory characteristics, since
it competes with omega-6 fatty acids for the same enzy-
matic pathway, leading to the inhibition of TNF-, IL-1 and IL-6
synthesis and reducing the intercellular adhesion molecule-1
(ICAM-1) expression.42 It is also a substrate for the synthesis
of series 3 and 5 eicosanoids, which have less inﬂammatory
characteristics (Fig. 2).6
Studies in cultured cells have further demonstrated that
EPA and DHA can inhibit the production of classic inﬂamma-
tory cytokines, such as TNF-, IL-1, IL-6, and others.40,43–45 In
healthy subjects, reduced production of TNF-, IL-1 and IL6 by
monocytes and mononuclear cells has already been demon-
strated following ﬁsh oil supplementation,9,10,46 although
other studies have not conﬁrmed those ﬁndings.8,47,48 These
differences might have occurred because of the different doses
used, the duration of treatment, and non-representative sam-
ples.
T-cell proliferation inhibition and IL-2 production were also
found in cultured cells following supplementation with EPA
and DHA.49 However, these ﬁndings are inconsistent in human
studies.
In addition, EPA and DHA are precursors of the lipid medi-
ators resolvins and protectins. The pathway for production
of theses mediators also involves the enzymes cyclooxygen-
ase and lipoxygenase (Fig. 2). In cultured-cell and animal
studies, both resolvins and protectins demonstrated to have
anti-inﬂammatory and immunomodulating actions.11–13,50
Resolvins E1 and D1 and protectin D1 can inhibit neutrophiltransendothelial migration, thus preventing the inﬁltration of
immune cells at the inﬂammation site. Resolvin E1 can fur-
ther inhibit IL-1 production and protectin E1 inhibits IL-1 and
TNF- production.50 Thus, these lipid mediators can play a role
in the resolution phase of inﬂammation and in limiting tissue
damage.
Thus, the ratio between daily intake of omega-6 and
omega-3 fatty-acid sources assumes great importance in
human nutrition.36 However, the Western diet is characterized
by a high omega-6 polyunsaturated fatty acid intake and high
omega-6/omega-3 ratio, which favors pathogenesis in a num-
ber of conditions, including cardiovascular, inﬂammatory, and
autoimmune diseases, as well as cancer. The omega-6/omega-
3 ratio in Western diet is estimated to be 15-20:1. On  the
other hand, an increased omega-3 intake and a reduced ratio
between these fatty acids as a consequence seems to exert a
suppressive effect on disease pathogenesis.51
Omega-3  and  Systemic  Lupus  Erythematosus
Few studies investigating omega-3 fatty acid effects on sub-
jects with SLE have been conducted to this moment. However,
a few trials suggest that supplementation with this class of
lipids can represent an additional therapy to the standard
pharmacological treatment of this disease due to their anti-
inﬂammatory properties.17–25
A difference in erythrocyte and plasma fatty acid level
between individuals with SLE and individuals without SLE
seems to exist. However, it is not known whether this dif-
ference occurs due to an inappropriate diet or the disease
itself. Aghdassi et al. (2011) compared the content of red cell
and plasma fatty acids between women with SLE and con-
trols, between patients with SLE with or without a history of
cardiovascular disease (CVD) and between patients taking or
not prednisone. Lower levels of omega-3 (EPA + DHA) and EPA
alone were found in red-cell membranes of individuals with
SLE compared with healthy individuals. On the other hand, no
signiﬁcant differences for fatty acid content between patients
and controls were found in plasma. In addition, patients with
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LE and a history of CVD had higher levels of plasma monoun-
aturated fatty acids and higher levels of omega-6 family
olyunsaturated fatty acids than those without CVD. Patients
aking prednisone had higher levels of omega-3 and lower
A/EPA ratios compared with those not taking prednisone.
owever, these differences were not statistically signiﬁcant.23
Low levels of omega-3 could contribute to worsen the
nﬂammation already present in these patients, thus indi-
ating that the nutrient supplementation, on its turn, would
ontribute to improve the inﬂammatory proﬁle and, conse-
uently, the disease activity, as substantiated by Elkan et al.
2012) in a study conducted in 114 patients with SLE and
22 subjects without the disease. The authors found that
igher levels of EPA and DHA in fat cells of patients with SLE
ere negatively associated with disease activity (measured
y Systemic Lupus Erythematosus Disease Activity Index –
LEDAI) and the presence of atherosclerotic plaques. On the
ther hand, higher omega-6 levels were positively associ-
ted with a higher damage index (evaluated by the Systemic
upus International Collaboration Clinics/American College of
heumatology Damage Index – SLICC/ACR) and the presence
f atherosclerotic plaques. In this study, food intake evaluation
dentiﬁed that subjects with SLE described a higher carbo-
ydrate intake and a lower ﬁber and polyunsaturated fatty
cid (omega-6 and omega-3) intake than controls. Carbohy-
rate intake was positively associated with the amount of
mega-6 fatty acids present in adipose tissue. An association
etween carbohydrate, ﬁber, saturated and monounsaturated
atty acid intake and disease activity or damage index could
ot be found.24
The ﬁrst study evaluating the effect of omega-3 fatty acids
n patients with SLE taking ﬁsh oil supplementation was
eported in 1989 by Clark et al. The authors analyzed the
ffects of omega-3 (EPA and DHA) on 12 subjects with SLE and
ephritis and concluded that diet supplementation with ﬁsh
il can affect the mechanisms involved in inﬂammation and
therosclerosis. The patients were given a supplementation
ver ﬁve weeks with daily doses of 6 g of ﬁsh oil, followed by
 period of ﬁve weeks without the supplementation and then
ve more  weeks with 18 g of ﬁsh oil daily. A rise in EPA and DHA
evels in membrane phospholipids and reduced AA incorpora-
ion were found. These changes were associated with reduced
latelet aggregation and blood viscosity and with an increase
n red cell ﬂexibility. LTB4 production by neutrophils was also
igniﬁcantly reduced. The higher ﬁsh oil dose induced 38%
eduction in triglyceride levels and a 39% reduction in VLDL-
holesterol, associated with a 28% increase in HDL-cholesterol
evels. The effects on the anti-DNA antibodies title and albu-
inuria was not veriﬁed.17
On the other hand, in another trial conducted by the same
roup of investigators, different results were found. In 21
atients with a stable lupus nephritis who  were given a daily
ose of 15 g ﬁsh oil or placebo containing olive oil over one
ear, an improvement in kidney function or in the disease
ctivity was not found in the ﬁsh oil group compared with the
lacebo group. As for blood lipids, only VLDL-cholesterol and
riglycerides had a signiﬁcant reduction following the treat-
ent with ﬁsh oil, whereas LDL and HDL fractions remained
nchanged.19 4;5 4(6):459–466 463
Westberg et al. (1990) evaluated the effects of omega-3 fatty
acids supplementation with capsules containing ﬁsh oil or
capsules of olive oil as a placebo in 60 patients with mod-
erately active SLE. Over the ﬁrst three months, the patients
receiving omega-3 supplementation had signiﬁcant improve-
ment in clinical and laboratory parameters. However, after a
six-month supplementation, no differences between groups
could be detected, which suggests, according to the authors,
the supplement effects are short-lived.18
In 2004, Duffy et al. published another trial evaluating
the effect of omega-3 supplements and/or copper in patients
with SLE. Fifty-two patients were divided into four treat-
ment groups. One of the groups was given 3 g of ﬁsh oil
in capsules (EPA 540 mg  + DHA 360 mg/capsule) and 3 mg
of copper; the second group was given 3 g of ﬁsh oil and
copper as a placebo; the third group received a supplement
with 3 mg  of copper and ﬁsh oil placebo; the fourth group
received placebo instead of both nutrients. After a six-month
supplementation, a reduced disease activity from 6.12 to 4.69
(P < 0.05), measured by the Systemic Lupus Activity Mea-
sure (SLAM) score, was found. The integument, neuromotor,
and laboratory domains of SLAM-R were most affected by
supplementation.20
Omega-3 beneﬁcial effects on reducing lupus nephritis
activity were evaluated by Nakamura et al. (2005). The authors
examined the effect of daily supplementation with 1.8 g of
puriﬁed EPA in six patients with lupus nephritis diagnosed
by kidney biopsy. After a 3-month supplementation, reduced
AA levels and increased levels of EPA in plasma phospho-
lipids were detected, in addition to reduced urinary levels of
8-isoprostane (from 550 113 pg/mg CR to 235 49 pg/mg CR,
P = 0.02). In the authors’ opinion, these ﬁndings indicate that
EPA can promote decreased oxidative stress, with consequent
beneﬁts for lupus nephritis treatment. On the other hand,
when immune parameters were evaluated, no signiﬁcant dif-
ferences were found in anti-DNA and serum complement
values after omega-3 treatment.21
Wright et al. (2008) compared the effects of daily intake of 3
g of omega-3 (1.200 mg  of DHA + 1.800 mg  of EPA) with placebo
of olive oil in 60 patients with SLE over a 24-week period.
They noted that the omega-3 supplementation in patients
with SLE could not only have a therapeutic effect on the dis-
ease activity measured through the Systemic Lupus Activity
Measure (SLAM-R) and British Isles Lupus Assessment Group
(BILAG) indexes, but also promote improvement in endothelial
function and reduced oxidative stress, thus conferring cardio-
vascular beneﬁts.22
Recently, Bello et al. (2013) have published a double-blind,
placebo-controlled trial in which 85 patients with SLE were
randomized to receive either 3 g of omega-3 supplements or
placebo. After a 12-week supplementation, no signiﬁcant dif-
ferences between the groups were found for disease activity,
serum levels of inﬂammatory markers (ICAM-1, VCAM-1, and
IL-6), and endothelial function. As for the lipid proﬁle, patients
receiving omega-3 had a signiﬁcant increase in LDL cholesterol
levels, whereas those in the placebo group had a signiﬁcant
25reduction of this lipoprotein.
Studies evaluating the effect of omega-3 fatty acids on SLE
are listed in Table 1.
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Table 1 – Interventional studies with omega-3 fatty acids in patients with systemic lupus erythematosus (SLE).
Study n Study design Results
Clark et al., 198917 12 subjects with lupus
nephritis
6  g of omega-3 supplements/day
over ﬁve weeks, followed by ﬁve
weeks with no supplements and
additional ﬁve weeks with 18 g of
omega-3/day
Rise in EPA and DHA levels in
membrane phospholipids and
decrease in AA levels
Decreased platelet aggregation and
blood viscosity
Increased red-cell ﬂexibility
Reduced LTB4 production by
neutrophils
38% reduction in triglyceride levels
and 39% reduction of VLDL-C levels
28% increase in HDL-C levels
No effects on anti-DNA and
albuminuria levels
Westberg et al., 199018 60 subjects with
moderately active SLE
Omega-3 supplements vs. placebo
Supplements for six months
Improvement in clinical and
laboratory parameters over the ﬁrst
three months with supplements
Unchanged after six months with
supplements
Clark et al., 199319 21 subjects with stable
lupus nephritis
Supplements with 15 g of ﬁsh oil
vs. olive oil placebo for one year
Unchanged kidney function and
disease activity
Reduced VLDL-C and triglyceride
serum levels
Unchanged LDL-C and HDL-C levels
Duffy et al., 200420 52 subjects with SLE Four groups: (1) 3 g of omega-3 + 3
mg of copper; (2) 3 g of
omega-3 + copper placebo; (3) 3 mg
of copper + omega-3 placebo; (4)
omega-3 and copper placebo
Supplements for six months
Reduced disease activity in groups
receiving omega-3
Nakamura et al., 200521 Six subjects with lupus
nephritis
Supplements with daily doses of
1.8 g of puriﬁed EPA
Supplements for three months
Reduced AA levels and increased
EPA levels in membrane
phospholipids
Reduced urine levels of 8
isoprostane
Unchanged anti-DNA and serum
complement values
Wright et al., 200822 60 subjects with SLE Supplements with 3 g/day of
omega-3 vs. olive oil placebo
Supplements for six months
Reduced disease activity
Improvement of endothelial
function
Reduced oxidative stress
Aghdassi et al., 201123 32 subjects with SLE and 20
controls without the
disease
Fatty  acid contents in red cells and
plasma from: women with and
without SLE; between SLE patients
with and without a history of CVD;
between patients taking
corticosteroids or not were
compared
Lower omega-3 levels in red-cell
membrane of subjects with SLE
than in those without the disease
Higher plasma omega-6 fatty-acid
levels in patients with SLE and a
history of CVD
Higher omega-3 levels in patients
taking corticosteroids
Differences, however, were not
statistically signiﬁcant
Elkan et al., 201224 114 SLE patients and 122
subjects without the
disease
Omega-3 and omega-6 contents in
adipose tissue cells of patients
with SLE were evaluated
Negative association between
higher EPA and DHA levels in
adipose tissue cells and disease
activity and presence of
atherosclerotic plaques
Positive association between higher
omega-6 levels in adipose tissue
cells, damage index, and presence
of atherosclerotic plaques
Bello et al., 201325 85 subjects with SLE Supplements with 3 g of
omega-3/day vs. placebo
Supplements for 12 weeks
Unchanged endothelial function
and disease activity
Increased LDL-C levels in subjects
receiving omega-3
Unchanged levels of inﬂammatory
markers (IL-6, ICAM-1, and
VCAM-1)
SLE, systemic lupus erythematosus; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; LT, leukotriene; VLDL-C, very-low-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; AA, arachidonic acid; CVD,
cardiovascular disease; IL, interleukin; ICAM, intercellular adhesion molecule; VCAM, vascular adhesion molecule.
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inal  remarks
linical studies suggest that supplementation with omega-3
olyunsaturated fatty acids can represent an additional option
o SLE standard pharmacological treatment because of their
nti-inﬂammatory properties.17–25 This lipid class is related
o the production of eicosanoids with a lower inﬂammatory
ction than those produced by fatty acids pertaining to the
mega-6 family, additionally reducing serum levels of inﬂam-
atory cytokines and T lymphocyte activation.
Clinical trials conducted used very different doses, ran-
ing from 1.8 g to 18 g of ﬁsh oil, and different treatment
engths, ranging from ﬁve weeks to 12 months. Whether pos-
tive effects are caused by EPA intake, DHA intake or by a
ombined action of both fatty acids is questionable. In addi-
ion, most studies have small numbers of subjects included,
herefore leading to limited conclusions.
Thus, further studies with a larger number of subjects
re needed to evaluate the real effect of these fatty acids in
atients with SLE, the effective dose, and the duration of treat-
ent.
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